Ildong Pharmaceutical Promotes New Drug Pipeline at 'BIO USA'

[Asia Economy Reporter Lee Gwan-joo] Ildong Pharmaceutical announced on the 16th that it participated in the '2022 BIO International Convention (BIO USA)' to promote its pipeline and new drug candidates.

BIO USA is the world's largest exhibition in the pharmaceutical and biotechnology fields, and this year it was held as an in-person event in San Diego, USA, for the first time in three years.

Through partnering meetings, Ildong Pharmaceutical unveiled its R&D pipeline related to ▲diabetes ▲liver diseases ▲ophthalmic diseases ▲respiratory diseases ▲gastrointestinal diseases ▲cancer, and sought collaboration partners and technology transfers.

The company also explained that it pursued open innovation with other companies in fields such as cancer and rare diseases, explored business opportunities through licensing-in, and conducted item discovery activities.

Currently, Ildong Pharmaceutical possesses more than 10 new drug pipelines, including 'IDG16177' with a GPR40 (G protein-coupled receptor 40) mechanism undergoing Phase 1 clinical trials in Germany, 'ID110521156' of the GLP-1 receptor agonist class at the preclinical stage for type 2 diabetes treatment, and an FXR (farnesoid X receptor) agonist mechanism non-alcoholic steatohepatitis (NASH) treatment expected to enter global Phase 1 clinical trials within this year.

An Ildong Pharmaceutical official stated, “During the event, we held active business meetings with over 60 overseas companies through the partnering program,” adding, “In particular, our pipelines for metabolic diseases and ophthalmic diseases attracted interest and positive responses from counterpart companies.”

This content was produced with the assistance of AI translation services.